TEMOZOLOMIDE (TMZ) CHEMOTHERAPY
FOR GLIOBLASTOMA

Temozolomide is an oral alkylating agent — it damages DNA in tumour cells by adding methyl groups to guanine residues, causing DNA strand breaks that trigger cancer cell death. Its key advantage over earlier alkylating agents is its ability to cross the blood-brain barrier effectively.

• DNA Methylation and Strand Breaks

  TMZ is converted spontaneously at physiological pH to the active compound MTIC, which methylates the O6 position of guanine in tumour cell DNA. If unrepaired, this triggers DNA strand breaks and apoptosis. Normal cells and cancer cells with intact repair mechanisms can partially neutralise this damage — which is why MGMT status matters.

• Oral Bioavailability and BBB Penetration

  TMZ has near-complete oral bioavailability (>96%) — meaning the tablet and IV forms are therapeutically equivalent. It crosses the blood-brain barrier reliably, achieving CNS penetration of approximately 35–40% of plasma concentration — sufficient for pharmacological activity against intracranial disease.

MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme that directly reverses TMZ's cytotoxic DNA damage. When the MGMT gene promoter is methylated, MGMT expression is silenced — and TMZ's damage accumulates, killing the cancer cell.

“MGMT methylation status is not just a prognostic marker — it is the most important predictive biomarker in GBM treatment. A patient with unmethylated GBM receiving TMZ is receiving a treatment that has minimal activity in their tumour. That information changes everything.”

• MGMT-Methylated GBM: Strong TMZ Benefit

  Approximately 40–50% of GBM patients have MGMT promoter methylation. These patients achieve median OS of 21–23 months with Stupp + TMZ — significantly better than unmethylated patients. TMZ adjuvant therapy is strongly recommended. Extended adjuvant TMZ (beyond 6 cycles) is not established as beneficial.

• MGMT-Unmethylated GBM: Minimal TMZ Benefit

  Approximately 50–60% of GBM patients are MGMT-unmethylated. These patients have median OS of 12–14 months with Stupp protocol and derive significantly less survival benefit from TMZ. Many oncologists and neuro-oncology guidelines recommend discussing trial alternatives from the outset for unmethylated patients rather than defaulting to standard adjuvant TMZ.

The Stupp protocol defines two distinct TMZ dosing phases — each with different dose, schedule, and monitoring requirements.

Most GBM patients tolerate TMZ reasonably well — but specific side effects require active monitoring and management. Proactive anti-emetic and infection prevention are essential.

• Nausea and Vomiting

  The most common TMZ side effect — particularly in the concurrent phase. Prevention: take TMZ on an empty stomach 1 hour before sleep (reducing nausea during waking hours) with a prophylactic anti-emetic (ondansetron or metoclopramide). If breakthrough nausea occurs, discuss ondansetron dosing adjustment with your oncologist.

• Myelosuppression (Low Blood Counts)

  TMZ can reduce white blood cells, platelets, and red blood cells — nadir occurs approximately day 22–28 of each adjuvant cycle. Full blood count (FBC) at day 22 of each cycle is mandatory before proceeding to the next cycle. Grade 3–4 cytopaenia requires dose reduction or cycle delay. Patients should report fever, bruising, or unusual fatigue immediately.

• PCP Prophylaxis: Non-Negotiable

  Concurrent TMZ + dexamethasone (used for cerebral oedema) causes significant immunosuppression — creating risk of Pneumocystis jirovecii pneumonia (PCP), which is life-threatening. Prophylactic co-trimoxazole (trimethoprim-sulfamethoxazole, 960 mg three times weekly) must be taken throughout the concurrent RT + TMZ phase. Patients allergic to sulfonamides should discuss pentamidine or atovaquone with their oncologist.

• Pseudoprogression: What It Is and Why It Matters

  MRI at 4–6 weeks after completing concurrent chemoradiation frequently shows apparent tumour enlargement — in 20–30% of cases this is pseudoprogression (treatment-related inflammation, not true tumour growth). Misinterpreting pseudoprogression as tumour progression and stopping TMZ prematurely is a significant clinical error. Perfusion MRI, MR spectroscopy, or repeat imaging after 4–6 weeks is used to differentiate at specialist centres.

GBM almost always recurs — the median time to recurrence on Stupp protocol is 6–9 months. Understanding what happens next before it occurs allows time to plan.

• 14–16 moMedian OS — Stupp Protocol (Overall GBM Population)vs 12 months with RT alone (Stupp 2005 NEJM trial)
• 21–23 moMedian OS — MGMT-Methylated + TMZThe subgroup with the greatest absolute TMZ benefit
• 40–50%Prevalence of MGMT Methylation in GBMTest mandatory before starting — defines treatment strategy
• ~30%Pseudoprogression Rate at 4–6 Weeks Post-CRTCritical to distinguish from true progression before stopping TMZ

Further guides on GBM treatment and advanced options.

Frequently Asked Questions